481 related articles for article (PubMed ID: 27349564)
1. Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume.
Chiu PK; Roobol MJ; Teoh JY; Lee WM; Yip SY; Hou SM; Bangma CH; Ng CF
Int Urol Nephrol; 2016 Oct; 48(10):1631-7. PubMed ID: 27349564
[TBL] [Abstract][Full Text] [Related]
2. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
3. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
Bohnen AM; Groeneveld FP; Bosch JL
Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
[TBL] [Abstract][Full Text] [Related]
5. Prostate volume predicts high grade prostate cancer both in digital rectal examination negative (ct1c) and positive (≥ct2) patients.
Yilmaz H; Ustuner M; Ciftci S; Yavuz U; Ozkan TA; Dillioglugil O
Int Braz J Urol; 2014; 40(5):613-9. PubMed ID: 25498272
[TBL] [Abstract][Full Text] [Related]
6. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography.
Yu GP; Na R; Ye DW; Qi J; Liu F; Chen HT; Wu YS; Zhang GM; Sun JL; Zhu Y; Huang LQ; Ren SC; Jiang DK; Zheng SL; Jiang HW; Sun YH; Ding Q; Xu J
Asian J Androl; 2016; 18(4):633-8. PubMed ID: 26975483
[TBL] [Abstract][Full Text] [Related]
7. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for prostate cancer patients with intermediate PSA levels.
Tanaka N; Fujimoto K; Chihara Y; Torimoto M; Hirao Y; Konishi N; Saito I
Prostate Cancer Prostatic Dis; 2007; 10(3):274-8. PubMed ID: 17339878
[TBL] [Abstract][Full Text] [Related]
8. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
9. Relative contribution of digital rectal examination and transrectal ultrasonography in interpreting serum prostate-specific antigen values for screening prostate cancer in Arab men.
Sheikh M; Sinan T; Kehinde EO; Hussein AY; Anim JT; Al-Hunayan AA
Ann Saudi Med; 2007; 27(2):73-8. PubMed ID: 17356323
[TBL] [Abstract][Full Text] [Related]
10. A Nomogram Based on a TRUS Five-Grade Scoring System for the Prediction of Prostate Cancer and High Grade Prostate Cancer at Initial TRUS-Guided Biopsy.
Xie SW; Wang YQ; Dong BJ; Xia JG; Li HL; Zhang SJ; Li FH; Xue W
J Cancer; 2018; 9(23):4382-4390. PubMed ID: 30519343
[No Abstract] [Full Text] [Related]
11. [Relationship between screening by stratifying cases into groups on prostate specific antigen level and the positive rate of transrectal ultrasound guided systematic sextant prostate biopsy].
Cao XL; Gao JP; Han G; Tang J; Hong BF
Zhonghua Wai Ke Za Zhi; 2006 Mar; 44(6):372-5. PubMed ID: 16638344
[TBL] [Abstract][Full Text] [Related]
12. Prostatic volume and volume-adjusted prostate-specific antigen as predictive parameters for T1c prostate cancer.
Tanaka N; Fujimoto K; Yoshikawa M; Tanaka M; Hirao Y; Kondo H; Saito I
Hinyokika Kiyo; 2007 Jul; 53(7):459-65. PubMed ID: 17702178
[TBL] [Abstract][Full Text] [Related]
13. The outcomes of transrectal ultrasound guided biopsy of the prostate in a New Zealand population.
Lienert AR; Davidson PJ; Wells JE
N Z Med J; 2009 Jan; 122(1288):39-49. PubMed ID: 19182841
[TBL] [Abstract][Full Text] [Related]
14. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?
Teoh JY; Yuen SK; Tsu JH; Wong CK; Ho BSh; Ng AT; Ma WK; Ho KL; Yiu MK
Asian J Androl; 2015; 17(5):821-5. PubMed ID: 25652619
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
17. A 12-year follow-up of ANNA/C-TRUS image-targeted biopsies in patients suspicious for prostate cancer.
Tokas T; Grabski B; Paul U; Bäurle L; Loch T
World J Urol; 2018 May; 36(5):699-704. PubMed ID: 29275507
[TBL] [Abstract][Full Text] [Related]
18. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
[TBL] [Abstract][Full Text] [Related]
19. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project.
Littrup PJ; Kane RA; Mettlin CJ; Murphy GP; Lee F; Toi A; Badalament R; Babaian R
Cancer; 1994 Dec; 74(12):3146-58. PubMed ID: 7526969
[TBL] [Abstract][Full Text] [Related]
20. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
